See more : Onex Corporation (ONEXF) Income Statement Analysis – Financial Results
Complete financial analysis of Calyxt, Inc. (CLXT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Calyxt, Inc., a leading company in the Packaged Foods industry within the Consumer Defensive sector.
You may be interested
- Profit Planners Management, Inc. (PPMT) Income Statement Analysis – Financial Results
- SRF Limited (SRF.NS) Income Statement Analysis – Financial Results
- Legacy Technology Holdings, Inc. (LTHO) Income Statement Analysis – Financial Results
- Belc CO., LTD. (9974.T) Income Statement Analysis – Financial Results
- Matsui Securities Co., Ltd. (8628.T) Income Statement Analysis – Financial Results
Calyxt, Inc. (CLXT)
About Calyxt, Inc.
Calyxt, Inc., a synthetic biology company, engages in delivering plant-based solutions primarily to the agriculture end market in the United States. The company is involved in the development of improved digestibility alfalfa; hemp; and wheat with a higher fiber content. It has a commercialization agreement with S&W Seed Company for the exclusive license of an improved quality alfalfa seed in the United States and internationally. The company was formerly known as Cellectis Plant Sciences, Inc. and changed its name to Calyxt, Inc. in May 2015. Calyxt, Inc. was incorporated in 2010 and is headquartered in Roseville, Minnesota. Calyxt, Inc. is a subsidiary of Cellectis S.A.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 157.00K | 25.99M | 23.85M | 7.30M | 236.00K | 508.00K | 399.00K | 1.27M |
| Cost of Revenue | 0.00 | 28.56M | 35.13M | 9.28M | 0.00 | 0.00 | 200.00K | 751.00K |
| Gross Profit | 157.00K | -2.57M | -11.28M | -1.98M | 236.00K | 508.00K | 199.00K | 521.00K |
| Gross Profit Ratio | 100.00% | -9.89% | -47.28% | -27.19% | 100.00% | 100.00% | 49.87% | 40.96% |
| Research & Development | 11.55M | 11.34M | 11.08M | 12.21M | 9.85M | 11.56M | 5.64M | 2.77M |
| General & Administrative | 0.00 | 0.00 | 16.16M | 18.97M | 18.51M | 14.74M | 6.67M | 3.57M |
| Selling & Marketing | 0.00 | 0.00 | 4.38M | 5.17M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 10.97M | 15.38M | 20.54M | 24.14M | 18.51M | 14.74M | 6.67M | 3.57M |
| Other Expenses | 5.57M | 45.00K | 252.00K | 1.34M | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 22.53M | 26.76M | 31.87M | 37.69M | 28.35M | 26.30M | 12.31M | 6.34M |
| Cost & Expenses | 22.53M | 55.32M | 67.00M | 46.97M | 28.35M | 26.30M | 12.51M | 7.09M |
| Interest Income | 60.00K | 17.00K | 557.00K | 1.60M | 1.52M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 75.00K | 1.43M | 1.44M | 1.49M | 1.26M | 1.00K | 5.00K | 261.00K |
| Depreciation & Amortization | 1.53M | 810.00K | 3.24M | 3.21M | 1.08M | 551.00K | 345.00K | 147.00K |
| EBITDA | -22.37M | -28.52M | -40.59M | -36.47M | -28.12M | -25.79M | -11.74M | -5.48M |
| EBITDA Ratio | -14,248.41% | -109.75% | -170.19% | -499.81% | -10,830.08% | -5,005.51% | -2,941.35% | -430.90% |
| Operating Income | -22.37M | -29.33M | -43.83M | -39.67M | -28.12M | -25.79M | -12.11M | -5.81M |
| Operating Income Ratio | -14,248.41% | -112.87% | -183.77% | -543.76% | -11,913.14% | -5,076.57% | -3,034.84% | -457.08% |
| Total Other Income/Expenses | 5.48M | 133.00K | -1.00M | 61.00K | 218.00K | -191.00K | 23.00K | -75.00K |
| Income Before Tax | -16.89M | -29.20M | -44.84M | -39.61M | -27.90M | -25.98M | -12.09M | -5.89M |
| Income Before Tax Ratio | -10,758.60% | -112.36% | -187.98% | -542.93% | -11,820.76% | -5,114.17% | -3,029.07% | -462.97% |
| Income Tax Expense | -7.09M | -114.00K | 1.56M | 1.49M | 1.48M | -190.00K | 28.00K | 186.00K |
| Net Income | -9.80M | -29.09M | -46.40M | -41.10M | -27.90M | -25.98M | -12.09M | -5.89M |
| Net Income Ratio | -6,243.95% | -111.92% | -194.54% | -563.35% | -11,820.76% | -5,114.17% | -3,029.07% | -462.97% |
| EPS | -10.66 | -38.81 | -68.47 | -62.64 | -0.91 | -1.12 | -0.45 | -0.22 |
| EPS Diluted | -10.66 | -38.81 | -68.47 | -62.64 | -0.91 | -1.12 | -0.45 | -0.22 |
| Weighted Avg Shares Out | 919.95K | 749.52K | 677.65K | 656.11K | 30.68M | 23.15M | 26.60M | 26.60M |
| Weighted Avg Shares Out (Dil) | 919.95K | 749.52K | 677.65K | 656.11K | 30.68M | 23.15M | 26.60M | 26.60M |
Calyxt (CLXT) Reports Q4 Loss, Tops Revenue Estimates
Calyxt (CLXT) delivered earnings and revenue surprises of -32.00% and 77.18%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Recap: Calyxt Q4 Earnings
-Shares of Calyxt (NASDAQ:CLXT) were flat after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 10.81% year over year to ($0.33), which missed the estimate of ($0.22).
Calyxt Reports Fourth Quarter and Full Year 2020 Financial Results
Continued to Progress Development of Winter Oats and Hemp, Both Targeted at Large Addressable Markets Secured Commitment from ADM to Purchase Remaining 2019 Grain Inventory and All 2020 Grain Production - Have Completed Sale of 40 Percent of 2020 Grain...
Should You Buy Calyxt (CLXT) Ahead of Earnings?
Calyxt (CLXT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Calyxt to Present at Upcoming March Investor Conferences
ROSEVILLE, MN / ACCESSWIRE / March 3, 2021 / Calyxt, Inc . (NASDAQ:CLXT), a plant-based technology company, will participate in the following investor conferences during the month of March 2021: Bank of America Securities 2021 Global Agriculture & Materials Virtual...
Calyxt Completes New Scientific Advisory Board with Key Appointments
World-Renowned Plant-Biochemistry Experts Named to Calyxt's Scientific Advisory Board Chaired by Company Co-Founder Dan Voytas, Ph.D. New Strategic Initiative to Identify High Value Plant-Derived Products Utilizing Calyxt's Proprietary Innovation Platform ROSEVILLE, MN / ACCESSWIRE / March 2, 2021 / Calyxt, Inc....
Calyxt powers advances in plant sciences, crop traits and building robust portfolio of products
Calyxt sells a premium soybean cooking oil Calyno TALEN gene-editing technology is a game-changer Strong management team with proven track record What Calyxt does: Calyxt Inc (NASDAQ:CLXT) is a plant-based technology company, which is developing healthier specialty food ingredients and...
Calyxt shares climb after Canaccord analyst doubles price target to $16, repeats 'Buy' rating
Calyxt Inc (NASDAQ:CLXT) shares jumped Tuesday after an analyst at Canaccord Genuity Capital markets doubled the firm's price target for the company from $8 to $16 and reiterated a "Buy" rating in a note to clients published late Monday. The...
Are You Looking for a Top Momentum Pick? Why Calyxt (CLXT) is a Great Choice
Does Calyxt (CLXT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Calyxt to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call on Thursday, March 4, 2021 at 4:30 p.m. Eastern Time
ROSEVILLE, Minn.--(BUSINESS WIRE)--Calyxt, Inc. (NASDAQ: CLXT), a plant-based technology company, will hold a conference call on Thursday, March 4, 2021 at 4:30 p.m. Eastern time to discuss its results for the fourth quarter and full year ended December 31, 2020....
Source: https://incomestatements.info
Category: Stock Reports